Evidence map›Paper›PMID 24755988›Full record

ArticleCancer biology & therapy2014

Inhibition of Notch signaling alters the phenotype of orthotopic tumors formed from glioblastoma multiforme neurosphere cells but does not hamper intracranial tumor growth regardless of endogene Notch pathway signature.

Karina Kristoffersen, Mette Kjølhede Nedergaard, Mette Villingshøj, Rehannah Borup, Helle Broholm, Andreas Kjær, Hans Skovgaard Poulsen, Marie-Thérése Stockhausen

Open access · bronzeAbstract read
In one paragraph

Article in Cancer biology & therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. IncreasedInternational journal of molecular sciences · 2024
    Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 3 countries.

Karina KristoffersenDepartment of Radiation Biology; The Finsen Center; Copenhagen University Hospital; Copenhagen, Denmark.
Mette Kjølhede NedergaardDepartment of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging; Copenhagen University Hospital and University of Copenhagen; Copenhagen, Denmark.
Mette VillingshøjDepartment of Radiation Biology; The Finsen Center; Copenhagen University Hospital; Copenhagen, Denmark.
Rehannah BorupCenter for Genomic Medicine; Copenhagen University Hospital; Copenhagen, Denmark.
Helle BroholmDepartment of Neuropathology; The Diagnostic Center; Copenhagen University Hospital; Copenhagen, Denmark.
Andreas KjærDepartment of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging; Copenhagen University Hospital and University of Copenhagen; Copenhagen, Denmark.
Hans Skovgaard PoulsenDepartment of Radiation Biology; The Finsen Center; Copenhagen University Hospital; Copenhagen, Denmark.
Marie-Thérése StockhausenDepartment of Radiation Biology; The Finsen Center; Copenhagen University Hospital; Copenhagen, Denmark.
Copenhagen University Hospital · DKUniversity of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBrain cancer stem-like cells (bCSC) are cancer cells with neural stem cell (NSC)-like properties found in the devastating brain tumor glioblastoma multiforme (GBM). bCSC are proposed a central role in tumor initiation, progression, treatment resistance and relapse and as such present a promising target in GBM research. The Notch signaling pathway is often deregulated in GBM and we have previously characterized GBM-derived bCSC cultures based on their expression of the Notch-1 receptor and found that it could be used as predictive marker for the effect of Notch inhibition. The aim of the present project was therefore to further elucidate the significance of Notch pathway activity for the tumorigenic properties of GBM-derived bCSC.

methodsHuman-derived GBM xenograft cells previously established as NSC-like neurosphere cultures were used. Notch inhibition was accomplished by exposing the cells to the gamma-secretase inhibitor DAPT prior to gene expression analysis and intracranial injection into immunocompromised mice.

resultsBy analyzing the expression of several Notch pathway components, we found that the cultures indeed displayed different Notch pathway signatures. However, when DAPT-treated neurosphere cells were injected into the brain of immunocompromised mice, no increase in survival was obtained regardless of Notch pathway signature and Notch inhibition. We did however observe a decrease in the expression of the stem cell marker Nestin, an increase in the proliferative marker Ki-67 and an increased number of abnormal vessels in tumors formed from DAPT-treated, high Notch-1 expressing cultures, when compared with the control.

conclusionBased on the presented results we propose that Notch inhibition partly induces differentiation of bCSC, and selects for a cell type that more strongly induces angiogenesis if the treatment is not sustained. However, this more differentiated cell type might prove to be more sensitive to conventional therapies.

Indexed as

AnimalsBrain NeoplasmsCell ProliferationCell SurvivalDipeptidesFemaleGene ExpressionGlioblastomaHeterograftsHumansMice, SCIDNeoplasm TransplantationNeoplastic Stem CellsReceptors, NotchSignal TransductionDipeptidesN-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl esterReceptors, Notchbrain cancer stem-like cellsDAPTglioblastoma multiformeneurosphere cultureNotch activityNotch signalingorthotopic xenograft

Identifiers

PMID24755988
PMCPMC4100987
OpenAlexW2001845064

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.